P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa

por Allen, MA, Gray, G, Churchyard, G, Bekker, L, Nchabeleng, M, Mlisana, K, Metch, B, Moodie, Z, Roux, S, Mathebula, M, Bennie, T, Kublin, J
Publicado 2009

Response definition criteria for ELISPOT assays revisited

por Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Löwer, M., Welters, M. J. P., Ottensmeier, C., van der Burg, S. H., Britten, Cedrik M.
Publicado 2010

P16-42. Characterisation of HIV-1 specific T-cell responses in exposed uninfected individuals from a London cohort

por Ritchie, AJ, Kopycinski, J, Campion, S, Moore, S, Liu, M, Tanner, R, Kuldanek, K, Legg, K, Wang, M, Moodie, Z, Korber, B, Fidler, S, McMichael, A, Goonetilleke, N
Publicado 2009

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

por Gray, GE, Bekker, L, Churchyard, G, Nchabeleng, M, Mlisana, K, de Bruyn, G, Roux, S, Mathebula, M, Latka, M, Bennie, T, Metch, B, Moodie, Z, Allen, M, Eaton, N, Kublin, J
Publicado 2009

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial

por Williams, WB, Jones, K, Krambrink, A, Grove, D, Liu, P, Yates, NL, Moody, MA, Ferrari, G, Pollara, J, Moodie, Z, Morgan, CA, Liao, H, Montefiori, DC, Ochsenbauer, C, Kappes, J, Hammer, S, Mascola, J, Koup, R, Corey, L, Nabel, G, Gilbert, P, Churchyard, G, Keefer, M, Graham, BS, Haynes, BF, Tomaras, GD
Publicado 2012